The Food and Drug Administration approved Alcon’s Brytly eye drops on Oct. 16 for relief of redness caused by minor eye irritations.
Brytly contains apraclonidine ophthalmic solution 0.125%. It is the first nonprescription eye drop containing apraclonidine, according to the FDA.
Alcon said in its Oct. 16 announcement that the product is expected at major retailers nationwide and online in the coming months.
The company maintains its principal U.S. operations office in Fort Worth, Texas, according to its 2025 annual report. The report also identifies Fort Worth as a production and research-and-development location for Alcon’s surgical and vision-care businesses.
